SCHEMBL639814

SCHEMBL639814

CCCCCCCC/C=C\CCCCCCCCO[PH](=O)O.[Ni]

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 3/20 0.53
LPAR1 Q92633 2/20 0.53
LPAR2 Q9HBW0 2/20 0.53
FAAH O00519 4/20 0.47
TRPV1 Q8NER1 1/20 0.47
TERT O14746 3/20 0.46
CYP1A2 P05177 2/20 0.46
MAPT P10636 2/20 0.46
CYP2C19 P33261 2/20 0.46
BLM P54132 2/20 0.46
HSD17B10 Q99714 2/20 0.46
FABP4 P15090 2/20 0.46
PTPN1 P18031 2/20 0.46
PPARG P37231 2/20 0.46
KMT2A Q03164 2/20 0.46
PPARD Q03181 2/20 0.46
PPARA Q07869 2/20 0.46
GMNN O75496 1/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3712984 0.98 LPAR3 (0.54) LPAR3LPAR1LPAR2FAAHTRPV1
SCHEMBL3719973 0.98 LPAR3 (0.54) LPAR3LPAR1LPAR2FAAHTRPV1
SCHEMBL672379 0.96 LPAR3 (0.53) LPAR3LPAR1LPAR2FAAHTRPV1
SCHEMBL7120722 0.96 LPAR3 (0.53) LPAR3LPAR1LPAR2FAAHTRPV1
Phosphonic Acid SCHEMBL28417856 0.96 LPAR3 (0.53) LPAR3LPAR1LPAR2FAAHTRPV1
SCHEMBL674424 0.96 LPAR3 (0.53) LPAR3LPAR1LPAR2FAAHTRPV1
SCHEMBL3962398 0.96 LPAR3 (0.53) LPAR3LPAR1LPAR2FAAHTRPV1
SCHEMBL7127580 0.96 LPAR3 (0.53) LPAR3LPAR1LPAR2FAAHTRPV1
Butane SCHEMBL3793662 0.96 LPAR3 (0.53) LPAR3LPAR1LPAR2FAAHTRPV1
SCHEMBL4918289 0.96 LPAR3 (0.53) LPAR3LPAR1LPAR2FAAHTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3969490-B1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND TIRE COMPONENTS BRIDGESTONE CORP (JP) 2026-03-25 EP disclosed
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-12-25 US disclosed
US-12410263-B2 Modified high-Cis polybutadiene polymer, related methods and rubber compositions BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) 2025-09-09 US disclosed
US-12264232-B2 Modified high-cis polybutadiene polymer, related methods and tire components BRIDGESTONE CORPORATION (JP) 2025-04-01 US disclosed
US-20250066516-A1 HYDROGENATED POLYBUTADIENE POLYMERS AND RUBBER COMPOSITIONS INCORPORATING SAME BRIDGESTONE CORPORATION (JP) 2025-02-27 US disclosed
CN-113825777-B Modified high cis polybutadiene polymers, related methods and tire components 株式会社普利司通 2025-01-28 CN disclosed
EP-4495146-A2 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS Bridgestone Americas Tire Operations, LLC (US) 2025-01-22 EP disclosed
EP-4457250-A1 HYDROGENATED POLYBUTADIENE POLYMERS AND RUBBER COMPOSITIONS INCORPORATING SAME Bridgestone Corporation (JP) 2024-11-06 EP disclosed
EP-3966259-B1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS BRIDGESTONE AMERICAS TIRE OPERATIONS LLC (US) 2024-10-30 EP disclosed
CN-118574860-A Hydrogenated polybutadiene polymer and rubber composition containing the same 株式会社普利司通 2024-08-30 CN disclosed
WO-2011047021-A1 PROCESSES FOR PREPARATION OF CYCLIC ACYCLIC DIENE COPOLYMER AND RUBBER COMPOSITION BRIDGESTONE CORPORATION (JP) 2011-04-21 WO disclosed
US-20100137520-A1 Branched Polymers and Methods for Their Synthesis and Use BRIDGESTONE CORPORATION (JP) 2010-06-03 US disclosed
US-7585805-B2 polymerization catalyst containing e.g.a combination or reaction product of triisobutylaluminum an alkylating agent, Ni(II) neodecanoate borate as nickel compound, trifluoride/n-hexanol complex as F2 compound and tin tetrachloride as Cl2 compound to polymerize 1,3-butadiene to cis-1,4-polybutadiene BRIDGESTONE CORPORATION 2009-09-08 US disclosed
EP-2066735-A2 BRANCHED POLYMERS AND METHODS FOR THEIR SYNTHESIS AND USE Bridgestone Corporation (JP) 2009-06-10 EP disclosed
US-20080255327-A1 addition polymerization of conjugated polyene monomer in the presence of polymerization catalysts comprising a mixture of a nickel-containing compound, an alkylating agent, a fluorine-containing compound, a carboxylic acid and an alcohol; controlling gelation, branching and molecular weight; efficiency BRIDGESTONE CORPORATION (JP) 2008-10-16 US disclosed
WO-2008045372-A2 BRANCHED POLYMERS AND METHODS FOR THEIR SYNTHESIS AND USE BRIDGESTONE CORPORATION (JP) 2008-04-17 WO disclosed
US-20070117942-A1 Nickel-based catalyst composition BRIDGESTONE CORPORATION 2007-05-24 US disclosed
EP-1788003-A1 Nickel-based catalyst composition Bridgestone Corporation (JP) 2007-05-23 EP disclosed
US-6699813-B2 COMPOSITION THAT IS COMBINATION OF OR REACTION PRODUCT OF LANTHANIDE COMPOUND, ALKYLATING AGENT, NICKEL-CONTAINING COMPOUND, AND OPTIONALLY HALOGEN-CONTAINING COMPOUND THAT INCLUDES ONE OR MORE LABILE HALOGEN ATOMS BRIDGESTONE CORPORATION (JP) 2004-03-02 US disclosed
US-20030176276-A1 Lanthanide-based catalyst composition for the manufacture of polydienes BRIDGESTONE CORPORATION (JP) 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250389555-A1 MODIFIED HIGH-CIS POLYBUTADIENE POLYMER, RELATED METHODS AND RUBBER COMPOSITIONS MALT1, INO80C, RTCB LPAR3 3513/4885LPAR1 3042/4885LPAR2 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.